In This Issue1
United States | Mexico | China | Poland | The Netherlands |
European Union | Italy
United States
A. U.S. Litigation
1. In re: Lantus Direct Purchaser Antitrust Litigation, Case No. 1:16-cv-12652 (D. Mass.)
On Oct. 27, 2026, Sanofi-Aventis U.S. and a group of drug wholesalers informed a Massachusetts federal court that they had agreed to resolve antitrust claims alleging that Sanofi improperly listed patents covering components of its Lantus SoloStar insulin pen in the FDA’s Orange Book to delay competing products. The settlement avoids a January trial and follows the court’s decision earlier this year denying cross-motions for summary judgment, in which the court found that although the patents should not have been listed in the Orange Book, a jury should decide whether Sanofi’s listings unlawfully restrained competition.